Anavex To Present Interim Phase 2a Clinical Trial Data Of ANAVEX 2-73 At Late-Breaking Oral Session Of CTAD 2015 Conference

NEW YORK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015.  The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.

Presentation Details

Title: New Exploratory Alzheimer's Drug ANAVEX 2-73: Assessment of Safety and
  Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer's
Date/Time: Saturday, November 7, 2015
  9:45 a.m. Central European Time (3:45 a.m. Eastern Time)
Location: Gran Hotel Princesa Sofia, Barcelona, Spain

The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts and a total of 32 mild-to-moderate Alzheimer's patients.  PART A is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days for each patient.  PART B is an open-label extension for an additional 52 weeks.

The primary objective of the trial is to evaluate the maximum tolerated dose of ANAVEX 2-73.  Secondary trial objectives include exploratory cognitive efficacy using mini-mental state examination score (MMSE), dose response, bioavailability, Cogstate and electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), as well as the relationship of ANAVEX 2-73 as an add-on therapy to donepezil (AriceptĀ®).

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Biotechs Bolstered on 21st Century Cures Passage

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield